6th TPD & Induced Proximity Summit Europe
March 10 – 12, 2026 | London, UK
Advancing PROTACs, molecular glues, and next-generation proximity-based therapeutics with enhanced safety and drug-like properties to drive clinical translation and unlock previously undruggable targets across oncology and wider disease areas.
The 6th TPD & Induced Proximity Summit Europe is Europe’s definitive meeting dedicated to proximity-based drug discovery. Showcasing innovations spanning PROTACs, molecular glues, stabilizers, and extracellular degraders, it highlights therapeutic advances across oncology, neurodegeneration, immunology, and rare diseases. Taking place in London in March 2026, the summit convenes over 80 CxOs, directors, senior scientists, and investors to drive the progression of proximity-based therapeutics from early discovery through to clinical translation.
5th Novel Conjugates Summit
March 17 – 19, 2026 | Boston, MA
Showcasing cutting-edge targeting formats and payload innovations designed to improve delivery, overcome resistance, and broaden the therapeutic potential of next-generation treatments across challenging disease areas.
Novel conjugates are rapidly emerging as one of the most competitive frontiers in precision oncology. With companies advancing beyond traditional ADCs, the focus is shifting toward new payload mechanisms and differentiated targeting formats to overcome resistance, widen therapeutic windows, address ADC-refractory cancers, and expand into non-oncology indications. The 5th Novel Conjugates Summit is the only industry meeting dedicated to offering deep insight into the most promising approaches, their advantages, and the future direction of this fast-evolving field.
8th Treg-Directed Therapies Summit
March 24 – 26, 2026 | Boston, MA
Advancing modulator and Treg cell therapies to accelerate clinical translation, redefine immune tolerance, and deliver transformative treatments for autoimmune, inflammatory, and neurodegenerative diseases.
With growing momentum—highlighted by Nobel recognition, Nektar Therapeutics’ clinical progress, and ORCA-T’s potential as the first FDA-approved Treg therapy—Treg therapeutics are entering a pivotal era. The 8th Treg-Directed Therapies Summit gathers leading experts from Quell Therapeutics, Nektar, Sanofi, Yale, and others to address challenges in cell targeting, mechanisms of action, cytokine biology, indication prioritization, GMP and regulatory pathways, clinical trial design, and validated efficacy endpoints to advance Treg therapies toward broader clinical success.
Neuroscience Innovation Pharma Partnering Summit
April 28-29 , 2026 | Boston, MA
Advance collaboration and partnerships across neurology and psychiatry to de-risk development, validate emerging technologies, and achieve improved biodistribution of safe, effective molecules targeting the central nervous system.
The Neuroscience Innovation Pharma Partnering Summit brings together pharma, biotech and investor leaders to accelerate collaboration in neurology and psychiatry. With a focus on CNS drug delivery, modality innovation and efficient partnering, the summit enables pre-scheduled one-on-one meetings and curated networking — including speed-matchmaking — to validate technologies, de-risk pipelines, and secure strategic alliances. It’s a targeted, high-impact forum to help safe, effective CNS therapies reach patients faster.
Search